Uterine size (cm3) ‐ · patients with uterine fibroids
1 finding from 1 review
Uterine bleeding · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of vasomotor symptoms · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of vasomotor symptoms ‐ · patients with uterine fibroids
GnRH‐a + medroxyprogesterone acetate may leads to lower rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).
1 finding from 1 review
Total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Live birth or ongoing pregnancy sensitivity analysis ‐ PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in live birth or ongoing pregnancy sensitivity analysis ‐ PCOS… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ PCOS (high‐responders)(micronised progesterone 100 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ PCOS… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation · assisted reproduction technology cycles
Summary of findings table ‐ Progestogen 1 showed no clear difference in oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus… compared with progestogen 2 (low certainty).
2 findings from 1 review
Oocyte pick‐up cancellation ‐ Normo‐responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol · assisted reproduction technology cycles
Summary of findings table ‐ Progestogen 1 showed no clear difference in oocyte pick‐up cancellation ‐ Normo‐responders (Dydrogesterone 20 mg… compared with progestogen 2 (moderate certainty).
1 finding from 1 review
Oocyte pick‐up cancellation · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation ‐ Normoresponders (micronised… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Intervention not reported
Acetazolamide versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide versus medroxyprogesterone: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk… (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Medroxyprogesterone versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in medroxyprogesterone versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Ovulation rate Ultrasound evidence of collapsed follicle or mid‐luteal serum progesterone < 10 ng/mL · women with anovulatory infertility undergoing ovulation induction with clomiphene citrate
Human chorionic gonadotrophin showed no clear difference in ovulation rate Ultrasound evidence of collapsed follicle or… compared with no ovulation trigger (low certainty).
1 finding from 1 review
OR 0.99 [0.36, 2.77]
305 participants
Low
Improvement in pain score (up to nine months after treatment): progesterone versus placebo · women with chronic pelvic pain
Medical treatment probably leads to higher improvement in pain score at end of treatment: progesterone versus… compared with placebo (moderate certainty).
2 findings from 1 review